Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | PTGER1 | P34995 | 6/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.41 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5651360 | 0.83 | BRD4 (0.52) | PTGER1 | |
| SCHEMBL6512936 | 0.77 | IMPDH2 (0.51) | SMN1; SMN2RAB9A | |
| SCHEMBL1110773 | 0.77 | SMN1; SMN2 (0.38) | CYP1A2HTTSMN1; SMN2RAB9A | |
| SCHEMBL23263138 | 0.76 | BRD4 (0.43) | MAOB | |
| SCHEMBL368071 | 0.73 | SLC6A4 (0.66) | SLC6A4MAOBPTGER1CCR5ALDH1A1 | |
| SCHEMBL31644088 | 0.73 | SLC6A4 (0.66) | SLC6A4MAOBPTGER1CCR5ALDH1A1 | |
| SCHEMBL4434864 | 0.72 | SLC6A4 (0.56) | SLC6A4MAOBPTGER1CCR5ALDH1A1 | |
| SCHEMBL17049367 | 0.72 | CCR5 (0.56) | SLC6A4MAOBPTGER1CCR5ALDH1A1 | |
| SCHEMBL17817809 | 0.71 | SGMS2 (0.52) | SLC6A4ALDH1A1HTTSMN1; SMN2RAB9A | |
| SCHEMBL17817812 | 0.71 | NPC1 (0.49) | SLC6A4CYP1A2ALDH1A1SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9440938-B2 | Sulfonamide derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20150158833-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO (JP) | 2015-06-11 | — | — | US | disclosed |
| US-8153793-B2 | Sulfonamide derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158833-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | PTGDR, PTGDR2, CNR2 | SLC6A4 1329/4885MAOB 3407/4885PTGER1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.